NCT04617925: Phase 2: EMN 27 - Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT04617925: Phase 2: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)

NCT04617925: Phase 2: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)

This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy.

Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up Phase.

Sponsor

European Myeloma Network

Collaborator

GlaxoSmithKline

---

ClinicalTrials.gov Identifier: NCT04617925

Official Title: A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

First Posted : November 5, 2020

Click here to see details on ClinicalTrials.gov

EMN27 - European Myeloma Network (myeloma-europe.org)

---

Belantamab mafodotin : National Cancer Institute

Belantamab mafodotin : MedlinePlus Drug Information

GSK2857916

---

Drug: Belantamab mafodotin

GSK2857916

---

Locations

Europe

United Kingdom

France

Germany

Greece

Italy

Netherlands